MDCX Medicus Pharma Ltd.

AI Employees for E-CommerceBeta

Unlock 24/7 fully automated AI staff for your online store. Experience the future of e-commerce operations—no humans required. Limited closed beta access!

Get Early Access →

Subscribe to $MDCX

Medicus Pharma Ltd.

Subscribe to $MDCX

$MDCX

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for Medicus Pharma Ltd.

Date	Price Target	Rating	Analyst

See more ratings

Medicus Pharma Ltd. Press Releases

Fastest customizable press release news feed in the world

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
PHILADELPHIA, March 06, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is pleased to announce a positively trending interim analysis for SKNJCT-003 Phase 2 clinical study to non-invasively treat basal cell carcinoma of the skin (BCC). The SKNJCT-003 clinical study is currently underway in nine (9) clinical sites in United States and is expected to randomize 60 patients. The interim analysis was conducted after more than 50% of the targeted 60 patients in the study were randomized. The interim analysis shows the clinical study SKNJCT-003 is trending positively with a proportion of subjects with complete clinical clearance of more than 60%. The
3/6/25 7:30:00 AM ET
$MDCX
Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)
PHILADELPHIA, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is pleased to announce that it has submitted a clinical design (SKNJCT-004) to UAE DOH to non-invasively treat BCC of the skin. The study is expected to randomize thirty-six (36) patients in four sites in UAE, which are Cleveland Clinic Abu Dhabi (CCAD), Sheikh Shakbout Medical City (SSMC), Burjeel Medical City (BMC), and American Hospital of Dubai (AHD). Insights Research Organization and Solutions (IROS), a UAE-based contract research organization, is coordinating the clinical study for the Company. IROS is a M42 portfolio company. Clinical Trial Desig
2/27/25 7:30:00 AM ET
$MDCX
Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)
PHILADELPHIA, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") is also pleased to announce that its phase 2 clinical study (SKNJCT-003) which is currently underway in nine (9) clinical sites in United States, has now randomized more than 50% of the 60 patients expected to be enrolled in the study. The Company also announced that it is on track to complete an interim data analysis before the end of Q1 2025 and to submit its findings to the United States Food and Drug Administration (FDA) as part of a package seeking a Type C meeting with the FDA in Q2 2025. The purpose of the Type C meeting is to formally discuss the product development and
2/14/25 7:30:00 AM ET
$MDCX
Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)
TORONTO and PHILADELPHIA, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company") today announced that it has entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by Yorkville Advisors Global, LP. Pursuant to the SEPA, the Company has the option, at its sole discretion, to sell up to US$15,000,000 of the Company's common shares (the "Shares") to the Investor at any time during the 36-months following the date of the SEPA. The Investor's obligation to purchase Shares is subject to a number of conditions, including that the Company file a registration statement with the Securit
2/11/25 7:30:00 AM ET
$MDCX
Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch
TORONTO and PHILADELPHIA, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) (TSXV:MDCX) ("Medicus" or the "Company") is pleased to announce that its Investigational New Animal Drug (INAD File No.013880) has received Minor Use in Major Species Designation ("MUMS") from the U.S. Food and Drug Administration ("FDA") for its dissolvable Doxorubin-containing microneedle array (D-MNA) to treat external squamous cell carcinoma (SCC) in horses. The company received a notification from the FDA on December 9th 2024. MUMS is a status similar to Orphan Drug status for human drugs. It entitles the company to an extended 7-year period of exclusive marketing following approval or condi
12/12/24 7:30:00 AM ET
$MDCX
Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region
TORONTO, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ:MDCX) (TSXV:MDCX) ("Medicus" or the "Company") is pleased to announce an agreement with Swanielle Inc. ("Swanielle") to explore expansion of Phase 2 clinical study for treatment of Basal Cell Carcinoma (BCC) in the Asia-pacific region. Under the agreement, Swanielle, a bespoke healthcare consulting firm, will help identify a pharmaceutical/biotech company or companies in Southeast Asia to partner with Medicus to expand the Phase 2 clinical study in the Asia Pacific region. The company is also pleased to announce that the phase 2 clinical study (SKNJCT-003) is currently underway in nine (9) clinical sites in United Sta
12/2/24 7:30:00 AM ET
$MDCX
Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer
TORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd (NASDAQ:MDCX, TSXV:MDCX) (the "Company") is pleased to announce the appointment of Faisal Mehmud, MD as Chief Medical Officer. "We are thrilled to welcome Dr. Mehmud to our leadership team," stated Dr. Raza Bokhari, Exec. Chairman & CEO. "Faisal has a proven track record in integrating cutting-edge science with practical, evidence-based medical strategies to develop partnerships and launch high impact therapies. We aim to capitalize on his experience and expertise to expand our drug development pipeline and foster collaboration with strategic partners to bring to market our novel non-invasive patented dissolvab
11/18/24 7:30:00 AM ET
$GSK
$MDCX
Biotechnology: Pharmaceutical Preparations
Health Care

Medicus Pharma Ltd.

Recent Analyst Ratings for Medicus Pharma Ltd.

Medicus Pharma Ltd.

Recent Analyst Ratings for Medicus Pharma Ltd.

Medicus Pharma Ltd. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Amendment: New insider Velocity Fund Partners, Lp claimed ownership of 3,323,741 shares (SEC Form 3)

Large owner Velocity Fund Partners, Lp sold $578,940 worth of Medicus Pharma LTD (75,000 units at $7.72) (SEC Form 4)

Amendment: SEC Form 3 filed by new insider Mehmud Faisal

Amendment: New insider Bokhari Raza claimed ownership of 793,173 shares (SEC Form 3)

Amendment: SEC Form 3 filed by new insider May Sara R.

Amendment: SEC Form 3 filed by new insider Lavelle Frank W

Amendment: SEC Form 3 filed by new insider Kaiser Larry

Amendment: SEC Form 3 filed by new insider Fishman Barry

Amendment: SEC Form 3 filed by new insider Ciaruffoli Robert J.

Amendment: SEC Form 3 filed by new insider Ashton William

Medicus Pharma Ltd. Press Releases

Fastest customizable press release news feed in the world

Medicus Pharma Ltd Announces Positively Trending Interim Analysis for SKNJCT-003 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Ltd Announces Submission of Phase 2 Clinical Design (SKNJCT-004) to United Arab Emirates (UAE) Department of Health (DOH) to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC)

Medicus Pharma Provides Update on SKNJCT-003 Phase 2 Clinical Study for the Treatment of Nodular Basal Cell Carcinoma (BCC)

Medicus Pharma Ltd. Enters into Standby Equity Purchase Agreement and Announces Intention to Voluntarily Delist from the TSX Venture Exchange (TSXV)

Medicus Pharma Ltd. Announces Minor Use (MUMS) Designation from the FDA for Doxorubicin-Containing Microneedle Array (D-MNA) Patch

Medicus Pharma Ltd. Announces Collaboration Agreement to Expand Phase 2 Clinical Study in Asia Pacific Region

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Medicus Pharma Ltd. Leadership Updates

Live Leadership Updates

Medicus Pharma Ltd. Appoints Faisal Mehmud, MD, MRCP as Chief Medical Officer

Medicus Pharma Ltd. SEC Filings

SEC Form S-1 filed by Medicus Pharma Ltd.

SEC Form S-1 filed by Medicus Pharma Ltd.

SEC Form 144 filed by Medicus Pharma Ltd.

SEC Form SCHEDULE 13G filed by Medicus Pharma Ltd.

SEC Form 253G2 filed by Medicus Pharma Ltd.

SEC Form 424B3 filed by Medicus Pharma Ltd.

SEC Form 10-Q filed by Medicus Pharma Ltd.

SEC Form 424B3 filed by Medicus Pharma Ltd.

SEC Form 253G2 filed by Medicus Pharma Ltd.

Medicus Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits